TWSTTwist Bioscience Corporation
$159.83+473% 1Y
$159.83
$25.4552 weeks$204.94
The financials
Twist Bioscience Corporation by the numbers
Twist Bioscience Corporation (TWST) reported revenue of $118M in Q3 2026 (quarter ended Jun 30, 2026), up 23% from the same quarter a year earlier. That came with a gross margin of 53% and net loss of $35M. For the full year FY2025, revenue was $377M (+20% year on year) and net income −$78M. Its largest product in Q3 2026 was Ngs Tools at $62M, 52% of the disclosed total, just ahead of Antibody Discovery at 48%. The next results filing is expected around Nov 13, 2026, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $118M | $96M | +23% |
| Gross profit | $62M | $51M | +22% |
| Operating income | −$36M | −$30M | n/a |
| Net income | −$35M | $20M | to a loss |
| Diluted EPS | −$0.56 | $0.33 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Ngs Tools | $62M | 52% |
| Antibody Discovery | $57M | 48% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q3 2026Total $118.4M (+6.9%)
Antibody Discovery grew +39% year on yearNgs Tools +12% year on year
Segment Latestquarter on quarteryear on year
- Ngs Tools$61.8M$61.8Mquarter on quarter +7.6%year on year +12%+7.6%+12%
- Antibody Discovery$56.6M$56.6Mquarter on quarter +6.2%year on year +39%+6.2%+39%
On our screens:Most shorted stocks
Diagnostics & Research
Ranks #20 of 21 by RyuScore